Minjee Kim

2 months ago | bcg.com | Daniel Küpper |Kristian Kuhlmann |Nathan Niese |Minjee Kim

Optimizing cell factories for next-generation technologies and strategically positioning them in an increasingly competitive market is key to long-term success. Battery cell production capacity globally could exceed demand by as much as twofold over the next five years, making operational efficiency essential to competitiveness.

Jul 7, 2024 | physiciansweekly.com | Minjee Kim

Stay connected to the latest news with Physician’s WeeklyInsights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues. Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons. SUBSCRIBE NOW

Jun 11, 2024 | aao-hnsfjournals.onlinelibrary.wiley.com | Minjee Kim |Anne Li |Anthony Prince |Ashwini Nadkarni

Corresponding Author Jennifer J. Shin MD, SM Department of Otolaryngology–Head and Neck Surgery, Harvard Medical School, Boston, Massachusetts, USA Center for Surgery and Public Health, Brigham and Women's Hospital, Boston, Massachusetts, USA Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts, USA Harvard Medical School, Harvard University, Boston, Massachusetts, USA Corresponding Author: Jennifer J.

Apr 25, 2024 | physiciansweekly.com | Minjee Kim

1. The hazard ratio for recurrence or death comparing sentinel node biopsy only to completion axillary lymph node dissection was non-significant (0.89) and below the noninferiority margin. 2. The overall survival rates at 5 years were similar between both groups, 92.9% vs 92%. Evidence Rating Level: 1 (Excellent)Study Rundown: Previous studies have challenged the necessity of completion axillary lymph node dissection in breast cancer treatment in certain patients.

Apr 24, 2024 | 2minutemedicine.com | Minjee Kim

1. The hazard ratio for recurrence or death comparing sentinel node biopsy only to completion axillary lymph node dissection was non-significant (0.89) and below the noninferiority margin. 2. The overall survival rates at 5 years were similar between both groups, 92.9% vs 92%. Evidence Rating Level: 1 (Excellent) Study Rundown: Previous studies have challenged the necessity of completion axillary lymph node dissection in breast cancer treatment in certain patients.